close icon

Campari Bulls to Get a Serious Hangover Soon

Campari is an Italian liquor and spirits maker with traditions dating back to 1860. The company’s stock price plunged sharply in March along with the markets in general and then recovered just as quickly to new records by year-end.

As shares hover near all-time highs, however, dark clouds appear to be gathering over the spirits industry once more. The U.S. is adding more varieties to its EU alcohol tariffs, hitting profits at Campari and its rivals by up to 6%. The truth, though, is that just by looking at the chart below, we would’ve been bearish even without the US-EU trade tensions.

Alcohol Tariffs to drag Campari stock into Elliott Wave correction

Campari ‘s weekly chart shows its entire share price history since its 2001 public debut in Milan. The uptrend from €0.54 twenty years ago to €9.87 in November is shaped like a textbook five-wave impulse. The pattern is labeled (1)-(2)-(3)-(4)-(5), where three smaller-degree impulses are visible within wave (3).

Tariffs Can Trigger a 46% Selloff in Campari Stock

Waves (2) unfolded during the 2008 Financial crisis, while last year’s coronavirus selloff fits in the position of wave (4). If this count is correct, the post-March surge must be wave (5). According to the Elliott Wave principle, we can expect a three-wave correction to follow every impulse.

Fifth waves are usually fully retraced by the negative phase of the cycle. In Campari ‘s case, this means a drop to roughly €5 a share is likely going forward. From the current price of €9.34, this translates into a ~46% decline.

Supporting the negative Elliott Wave outlook is a strong bearish RSI divergence between waves (3) and (5). Not to mention the hefty 44 price-to-earnings ratio Campari currently trades at. In our opinion, there are better places to look for value across stock markets in Europe.

Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

Lockheed ‘s Correction Still Unfolding as Expected

Almost a year and a half ago, in July 2019, we wrote that Lockheed Martin is likely “setting the stage for an unpleasant surprise.” The stock had just reached a new all-time high and was trading at $370 a share. Optimism was in the air and analysts were more bullish than ever. An indeed, fundamentally,…

Read More »

More analyses